Phase 3 N=517 MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 32 — -1.86; -1.39 Percent of glycosylated hemoglobin (A1C) — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=800 Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies
Lung Disease
Primary: Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress — 258; 262 Participants — p=0.7340
Phase 3 N=401 A Study for Patient With Chronic Low Back Pain
Chronic Low Back Pain
Primary: Change From Baseline to 12 Weeks in Brief Pain Inventory 24-hour Average Pain Score — -2.48; -1.80 units on a scale — p=0.001
Phase 3 N=354 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil
Vaccines, Pneumococcal Conjugate Vaccine
Primary: Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1…
Phase 3 N=9,016 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
Atrial Fibrillation · Cardiovascular Disease
Primary: First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication — 963; 963; 136; 123 participants — p=0.8570
Phase 3 N=204 Comparative Performance of PureVision Lens Designs
Myopia
Primary: Subjective Responses to Symptoms/Complaints — 80.0; 81.2 Visual Analogue Scale
Phase 3 N=663 Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
Fibrillation, Atrial
Primary: Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter — 129; 135; 140; 123 participants — p=0.263
Phase 3 N=267 Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain
Chronic Non-malignant Pain
Primary: The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase. — 89; 66; 155; 81 participants — p=.0217
Phase 3 N=511 Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
HIV Infections
Primary: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response…
Phase 3 N=488 A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 7.4; 9.2 Months — p=0.9986
Phase 3 N=25,086 Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
Acute Coronary Disease · Angina Unstable
Primary: First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison — 557; 522; 222; 226 participants — p=0.3037
Phase 3 N=305 Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.
Diabetes Mellitus · Dyslipidemias
Primary: The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol. — 3.2; -0.3 mg/dL — p=0.0018
Phase 3 N=1,035 A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
Type 2 Diabetes Mellitus, Non Insulin Dependent · Diabetes Mellitus, Non-Insulin-Dependent
Primary: Change From Baseline in HbA1c at Week 30 — -0.47; -0.54 Percent
Phase 3 N=146 Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)
Hypercholesterolemia
Primary: Number of Participants With Adverse Events and Adverse Reactions — 141; 61 Participants
Phase 3 N=645 Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Median Number of Months of Progression-free Survival (PFS) — 4.40; 4.24 Months — p=0.2358